Building in Healthcare: FDA Approval, Fundraising, and Team Motivation – Insights from BioticsAI CEO

In a candid conversation on Build Mode, BioticsAI CEO Robhy Bustami peeled back the curtain on what it really takes to build a healthtech company. He shared hard-won lessons about steering a startup through FDA approval, raising capital in a cautious market, and keeping a team fired up despite the heavy regulatory burden. While the red tape is legendary, Bustami revealed that it’s also a source of clarity and focus. Below, we break down his key insights into a series of questions and answers that get to the heart of building in healthcare.

How Did BioticsAI Navigate the FDA Approval Process?

Bustami explained that the first step was understanding that FDA approval isn’t just a hurdle—it’s actually a competitive moat. BioticsAI started by mapping out every regulatory requirement from the outset, not as an afterthought. They engaged with the FDA early through pre-submission meetings, which helped clarify what evidence would be needed. The team focused on building a rock-solid clinical validation pipeline, partnering with hospitals to collect real-world data. Bustami emphasized that transparency with the agency reduced guesswork and saved months of back-and-forth. A key tactic was to treat the FDA as a collaborator, not an adversary. This approach allowed BioticsAI to submit a clean application that moved through the review process faster than typical for its class. The CEO also noted that staying up to date with the agency’s evolving guidance on AI-based medical devices was crucial, and they invested in a dedicated regulatory affairs expert early on. As discussed later, this discipline also kept the entire team aligned on what “good” looks like.

What Fundraising Strategies Worked for BioticsAI in Healthcare?

Fundraising in healthtech is notoriously slow because investors demand both technical and regulatory de-risking. Bustami said BioticsAI took a phased approach: first raising a small seed round from angel investors who understood the regulatory maze, then using that capital to reach a clear milestone—such as FDA 510(k) clearance—before approaching VCs. This reduced perceived risk. He stressed the importance of storytelling that connects clinical outcomes to a scalable business model. BioticsAI also leveraged non-dilutive grants from organizations like the NIH and the NSF, which not only provided money but also external validation. Bustami warned against over-optimistic timelines; instead, he advised founders to show realistic, data-backed projections. Another smart move was to bring in a board member with regulatory experience, which gave investors confidence. The CEO noted that healthcare VCs are increasingly interested in AI, but they need to see a path to reimbursement—so BioticsAI engaged with payers early.

How Did You Keep the Team Motivated Despite the Red Tape?

Regulatory red tape can drain morale, especially for engineers who want to ship fast. Bustami countered this by framing compliance as a badge of honor. He regularly reminded the team that their work was literally saving lives and that every regulatory checkbox stood for patient safety. BioticsAI created a culture of small wins: celebrating each FDA submission milestone or positive audit. They also gave team members direct exposure to clinicians using their product, which made the mission tangible. Bustami instituted “regulatory office hours” where anyone could ask questions, turning a burden into a learning opportunity. He also tried to shield the technical team from unnecessary meetings, letting them focus on building while a small cross-functional group handled most regulatory coordination. The CEO admitted it’s an ongoing effort, but transparency about timelines and the “why” behind each requirement helped the team stay engaged. More on the broader reality below.

What Is the Real Reality of Building a Healthtech Company Today?

Bustami didn’t sugarcoat it: building in healthcare is slower, more expensive, and more uncertain than almost any other tech sector. The reality is that even with a great product, you need to factor in 18–24 months for regulatory clearance, then additional time for reimbursement decisions. The CEO highlighted that cash burn is much higher because you often need to pay for clinical studies and legal expertise before any revenue comes in. Another reality is the fragmented buyer landscape—selling to hospitals, insurers, and individual providers each requires different value propositions. Bustami noted that the biggest surprise was how much energy goes into education: explaining AI to risk-averse stakeholders. Yet, he also called it the most rewarding sector. Once you have regulatory approval, the barriers to entry for competitors are equally high. The key, he said, is to build a company that can endure the long maturation curve by choosing investors and partners who understand the timeline.

What Advice Would You Give to Other Healthtech Founders?

Bustami’s first piece of advice: start your regulatory conversations yesterday. Many founders underestimate how long it takes to gather the evidence needed for FDA clearance. He also urged founders to hire at least one person with deep regulatory expertise before you think you need them. Second, don’t just build for today’s rules—build flexible systems that can adapt as regulations evolve, especially for AI. Third, he advised against trying to do everything alone; partner with academic medical centers for validation and distribution. Fourth, be ready to pivot on your business model—BioticsAI originally considered a direct-to-clinic model but shifted to a B2B SaaS approach after listening to customer feedback. Finally, take care of your team’s mental health; the grind is real. Bustami recommended implementing regular check‑ins and celebrating every regulatory win, as covered earlier, to build resilience.

How Does Regulation Actually Drive Innovation, Not Stifle It?

Common perception says regulation kills innovation, but Bustami argued it can be a forcing function for rigor. Because BioticsAI had to prove clinical efficacy to the FDA, they developed a deeper understanding of their own algorithms’ strengths and limitations—which actually improved the product. The structured process forced them to document everything, leading to cleaner code and better reproducibility. He noted that the FDA’s focus on transparency also aligned with good engineering practices. Furthermore, regulatory clearance acts as a powerful marketing tool; hospitals trust a product that has been vetted by a federal agency. Bustami pointed out that many of the most innovative healthtech companies came from a regulatory-first mindset. Rather than fighting the system, they used it to prioritize features that mattered most to patient outcomes. In the end, regulation raised the bar for everyone, which ultimately benefits patients—and that’s the whole point of healthtech.